Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Retained Earnings (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Retained Earnings for 3 consecutive years, with -$330.5 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 256101.55% to -$330.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$330.5 million through Dec 2025, down 256101.55% year-over-year, with the annual reading at -$330.5 million for FY2025, 256101.55% down from the prior year.
  • Retained Earnings for Q4 2025 was -$330.5 million at Artiva Biotherapeutics, down from -$309.8 million in the prior quarter.
  • The five-year high for Retained Earnings was $121000.0 in Q2 2024, with the low at -$330.5 million in Q4 2025.
  • Average Retained Earnings over 3 years is -$200.9 million, with a median of -$248.8 million recorded in 2024.
  • The sharpest move saw Retained Earnings soared 99.93% in 2024, then tumbled 256101.55% in 2025.
  • Over 3 years, Retained Earnings stood at -$181.3 million in 2023, then skyrocketed by 99.93% to -$129000.0 in 2024, then crashed by 256101.55% to -$330.5 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$330.5 million, -$309.8 million, and -$288.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.